Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barry Bresnihan

Showing results (11-20 of 65) with videos related to

Pageof 7
Sort By:
The Journal of Rheumatology|June 2, 2004
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trialBarry Bresnihan, Richard Newmark, Sean Robbins, et al.
Arthritis and Rheumatism|November 13, 2002
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trialGeorge Nuki, Barry Bresnihan, Moraye B Bear, et al.
Arthritis and Rheumatism|April 13, 2004
Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissueAlice N McEvoy, Barry Bresnihan, Oliver FitzGerald, et al.
Clinical and Experimental Rheumatology|June 8, 2010
Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritisPatricia Minnock, John Kirwan, Douglas Veale, et al.
Annals of the New York Academy of Sciences|July 13, 2002
Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathwayAlice N McEvoy, Barry Bresnihan, Oliver Fitzgerald, et al.
Drugs|September 26, 2003
Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritisTrevor Duffy, Orina Belton, Barry Bresnihan, et al.
Arthritis Care & Research|June 27, 2014
How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal studyPatricia Minnock, Gabrielle McKee, Barry Bresnihan, et al.
Clinical Rheumatology|October 11, 2015
Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisPatricia Minnock, Douglas J Veale, Barry Bresnihan, et al.
Arthritis Research & Therapy|November 13, 2004
Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?Barry Bresnihan, Martina Gogarty, Oliver FitzGerald, et al.
Musculoskeletal Care|February 13, 2016
Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition TherapyPatricia Minnock, Anders Ringnér, Barry Bresnihan, et al.
Pageof 7

Showing results (11-20 of 65) with videos related to

Sort By:
Pageof 7
The Journal of Rheumatology|June 2, 2004
Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trialBarry Bresnihan, Richard Newmark, Sean Robbins, et al.
Arthritis and Rheumatism|November 13, 2002
Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trialGeorge Nuki, Barry Bresnihan, Moraye B Bear, et al.
Arthritis and Rheumatism|April 13, 2004
Cyclooxygenase 2-derived prostaglandin E2 production by corticotropin-releasing hormone contributes to the activated cAMP response element binding protein content in rheumatoid arthritis synovial tissueAlice N McEvoy, Barry Bresnihan, Oliver FitzGerald, et al.
Clinical and Experimental Rheumatology|June 8, 2010
Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritisPatricia Minnock, John Kirwan, Douglas Veale, et al.
Annals of the New York Academy of Sciences|July 13, 2002
Corticotropin-releasing hormone signaling in synovial tissue vascular endothelium is mediated through the cAMP/CREB pathwayAlice N McEvoy, Barry Bresnihan, Oliver Fitzgerald, et al.
Drugs|September 26, 2003
Inhibition of PGE2 production by nimesulide compared with diclofenac in the acutely inflamed joint of patients with arthritisTrevor Duffy, Orina Belton, Barry Bresnihan, et al.
Arthritis Care & Research|June 27, 2014
How much is fatigue explained by standard clinical characteristics of disease activity in patients with inflammatory arthritis? A longitudinal studyPatricia Minnock, Gabrielle McKee, Barry Bresnihan, et al.
Clinical Rheumatology|October 11, 2015
Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysisPatricia Minnock, Douglas J Veale, Barry Bresnihan, et al.
Arthritis Research & Therapy|November 13, 2004
Apolipoprotein A-I infiltration in rheumatoid arthritis synovial tissue: a control mechanism of cytokine production?Barry Bresnihan, Martina Gogarty, Oliver FitzGerald, et al.
Musculoskeletal Care|February 13, 2016
Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition TherapyPatricia Minnock, Anders Ringnér, Barry Bresnihan, et al.
Pageof 7